Tenon Medical, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
TNON$1.75+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows from Operating Activities | ||
| Net loss | $(12,556) | $(13,673) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,691 | 3,845 |
| Depreciation and amortization | 262 | 408 |
| Provision for losses on accounts receivable | 16 | 41 |
| Amortization of operating right-of-use asset | 268 | 247 |
| Increase (decrease) in cash resulting from changes in: | ||
| Accounts receivable | (851) | (386) |
| Inventory | (387) | (52) |
| Prepaid expenses and other assets | (35) | 183 |
| Accounts payable | 486 | (64) |
| Accrued expenses | 648 | (171) |
| Operating lease liability | (287) | (256) |
| Net cash used in operating activities | (10,745) | (9,878) |
| Cash Flows from Investing Activities | ||
| Purchase of assets from SiVantage, Inc. | (750) | — |
| Purchases of property and equipment | (273) | (186) |
| Net cash used in investing activities | (1,023) | (186) |
| Cash Flows from Financing Activities | ||
| Gross proceeds from issuance of common stock, prefunded warrants, and warrants | 4,010 | 4,500 |
| Gross proceeds from exercise of warrants under inducement agreement | 3,057 | 4,648 |
| Gross proceeds from issuance of common stock and warrants | 2,850 | — |
| Gross proceeds from issuance of Series A convertible preferred stock | — | 2,605 |
| Gross proceeds from issuance of Series B convertible preferred stock | — | 550 |
| Gross proceeds from issuance of common stock | — | 2,106 |
| Gross proceeds from exercise of warrants | — | 812 |
| Offering costs | (928) | (1,096) |
| Net cash provided by financing activities | 8,989 | 14,125 |
| Effect of foreign currency translation on cash flow | — | 46 |
| Net (Decrease) Increase in Cash and Cash Equivalents | (2,779) | 4,107 |
| Cash and Cash Equivalents at Beginning of Year | 6,535 | 2,428 |
| Cash and Cash Equivalents at End of Year | $3,756 | $6,535 |
| Supplemental Disclosures of Cash Flow Information | ||
| Non-cash investment and financing activities: | ||
| Warrant modification costs | $5,133 | $992 |
| Preferred stock issued upon conversion of debt and accrued interest | $— | $1,186 |
| Reclassification of deferred offering costs to additional paid-in capital | $421 | $367 |
| Common stock issued upon conversion of Series A preferred stock | $678 | $— |
| Common stock issued for purchase of assets from SiVantage, Inc. | $1,366 | $— |
| Contingent consideration for purchase of assets from SiVantage, Inc. | $1,011 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.